4.4 Article

Mutation in Chek2 triggers von Hippel-Lindau hemangioblastoma growth

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Genetics & Heredity

Genotype-phenotype correlations and clinical outcomes of patients with von Hippel-Lindau disease with large deletions

Kenan Zhang et al.

Summary: This study aimed to explore the genotype-phenotype correlations and clinical outcomes in von Hippel-Lindau (VHL) patients with large deletions (LDs). The results showed that the number of generations and the status of exon 2 could affect the age of onset of VHL-related manifestations, and age of onset was an independent risk factor for overall survival. Tyrosine kinase inhibitor (TKI) therapy was found to be effective in VHL patients with LDs.

JOURNAL OF MEDICAL GENETICS (2023)

Article Multidisciplinary Sciences

Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding

Juliana A. Martinez Fiesco et al.

Summary: In this study, cryo-electron microscopy structures were used to investigate the mechanism of RAS-mediated monomer-to-dimer transition of full-length BRAF.

NATURE COMMUNICATIONS (2022)

Article Multidisciplinary Sciences

PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism

Aileen A. Ren et al.

Summary: Vascular malformations are caused by increased signaling through the PI3K-mTOR pathway and loss of function of the CCM complex, which are found in the majority of human CCMs. Using mouse models, researchers discovered that the formation of CCMs can be effectively blocked by the mTORC1 inhibitor rapamycin.

NATURE (2021)

Article Biochemistry & Molecular Biology

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Toni K. Choueiri et al.

Summary: The HIF-2 alpha inhibitor belzutifan shows promising clinical activity and a favorable safety profile in heavily pre-treated patients with renal cell carcinoma, suggesting it may offer an effective treatment option. The drug was well tolerated with a confirmed objective response rate of 25% and a median progression-free survival of 14.5 months in patients with ccRCC.

NATURE MEDICINE (2021)

Letter Genetics & Heredity

CLN5 in heterozygosis may protect against the development of tumors in a VHL patient

Isabel de Rojas-P et al.

ORPHANET JOURNAL OF RARE DISEASES (2020)

Review Oncology

Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy

Isabel Heidegger et al.

FRONTIERS IN ONCOLOGY (2019)

Article Biochemistry & Molecular Biology

Predicting Splicing from Primary Sequence with Deep Learning

Kishore Jaganathan et al.

Article Biochemistry & Molecular Biology

Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling

Elizabeth M. Terrell et al.

MOLECULAR CELL (2019)

Article Genetics & Heredity

Evidence for genetic anticipation in von Hippel-Lindau syndrome

Laura Aronoff et al.

JOURNAL OF MEDICAL GENETICS (2018)

Review Clinical Neurology

Review of the Neurological Implications of von Hippel-Lindau Disease

David Dornbos et al.

JAMA NEUROLOGY (2018)

Article Genetics & Heredity

Survival and causes of death in patients with von Hippel-Lindau disease

Marie Louise Molgaard Binderup et al.

JOURNAL OF MEDICAL GENETICS (2017)

Article Multidisciplinary Sciences

Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma

Ondrej Havranek et al.

PLOS ONE (2015)

Article Biochemical Research Methods

The Sequence Alignment/Map format and SAMtools

Heng Li et al.

BIOINFORMATICS (2009)

Article Clinical Neurology

Pituitary stalk hemangioblastomas in von Hippel-Lindau disease

Russell R. Lonser et al.

JOURNAL OF NEUROSURGERY (2009)

Article Clinical Neurology

Somatic mutations in VHL germline deletion kindred correlate with mild phenotype

SD Wait et al.

ANNALS OF NEUROLOGY (2004)

Article Genetics & Heredity

CHEK2 is a multiorgan cancer susceptibility gene

C Cybulski et al.

AMERICAN JOURNAL OF HUMAN GENETICS (2004)

Review Medicine, General & Internal

von Hippel-Lindau disease

RR Lonser et al.

LANCET (2003)